Bristol-Myers Squibb Co, the maker of Excedrin painkillers, said it received a subpoena from the US Attorney in Boston over pricing and marketing of drugs covered by Medicare and Medicaid.
Last month, New York-based Bristol-Myers said it started an internal review of its sales and marketing practices to make sure they don't violate laws.
The drugmaker shared information about its probe with representatives of the US attorney, who then subpoenaed the company, according to a regulatory filing.
The internal review focuses on whether Bristol-Myers's practices comply with anti-kickback laws and pricing requirements under the Medicaid program, the drugmaker said in its filing with the US Securities and Exchange Commission.
Medicaid, which is funded by the US and states, is the government health-insurance program for the poor. Medicare is the US health-insurance program for the elderly and disabled.
Government prosecutors have been cracking down on drugmakers who failed to give the best price for a medicine to government health-insurance programs or whose marketing practices resulted in fraudulent reimbursement claims.
Bristol-Myers and other drug companies have received requests for documents from the Office of the Inspector General of the Department of Health and Human Services and several states as well as the US attorney in Boston.
The filing didn't say when the subpoena was received. The investigations could result in criminal or civil claims, according to the filing.
Shares of Bristol-Myers fell US$0.07 to US$26.02 as of 4:15pm in New York Stock Exchange composite trading.
Samantha Martin, a spokeswoman for the US attorney in Massachusetts, didn't return a call made Friday evening.
Taiwan Semiconductor Manufacturing Co (TSMC, 台積電) secured a record 70.2 percent share of the global foundry business in the second quarter, up from 67.6 percent the previous quarter, and continued widening its lead over second-placed Samsung Electronics Co, TrendForce Corp (集邦科技) said on Monday. TSMC posted US$30.24 billion in sales in the April-to-June period, up 18.5 percent from the previous quarter, driven by major smartphone customers entering their ramp-up cycle and robust demand for artificial intelligence chips, laptops and PCs, which boosted wafer shipments and average selling prices, TrendForce said in a report. Samsung’s sales also grew in the second quarter, up
LIMITED IMPACT: Investor confidence was likely sustained by its relatively small exposure to the Chinese market, as only less advanced chips are made in Nanjing Taiwan Semiconductor Manufacturing Co (TSMC, 台積電) saw its stock price close steady yesterday in a sign that the loss of the validated end user (VEU) status for its Nanjing, China, fab should have a mild impact on the world’s biggest contract chipmaker financially and technologically. Media reports about the waiver loss sent TSMC down 1.29 percent during the early trading session yesterday, but the stock soon regained strength and ended at NT$1,160, unchanged from Tuesday. Investors’ confidence in TSMC was likely built on its relatively small exposure to the Chinese market, as Chinese customers contributed about 9 percent to TSMC’s revenue last
LOOPHOLES: The move is to end a break that was aiding foreign producers without any similar benefit for US manufacturers, the US Department of Commerce said US President Donald Trump’s administration would make it harder for Samsung Electronics Co and SK Hynix Inc to ship critical equipment to their chipmaking operations in China, dealing a potential blow to the companies’ production in the world’s largest semiconductor market. The US Department of Commerce in a notice published on Friday said that it was revoking waivers for Samsung and SK Hynix to use US technologies in their Chinese operations. The companies had been operating in China under regulations that allow them to import chipmaking equipment without applying for a new license each time. The move would revise what is known
UNCERTAINTY: A final ruling against the president’s tariffs would upend his trade deals and force the government to content with billions of dollars in refunds The legal fight over US President Donald Trump’s global tariffs is deepening after a federal appeals court ruled the levies were issued illegally under an emergency law, extending the chaos in global trade. A 7-4 decision by a panel of judges on Friday was a major setback for Trump, even as it gives both sides something to boast about. The majority upheld a May ruling by the Court of International Trade that the tariffs were illegal. However, the judges left the levies intact while the case proceeds, as Trump had requested, and suggested that any injunction could potentially be narrowed to apply
RSS